All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-12-10T09:20:01.000Z

FDA approves rituximab-abbs for the treatment of adult patients with CD20-positive B-cell NHL

Dec 10, 2018
Share:

Bookmark this article

On 28 November 2018, rituximab-abbs (Truxima®), a monoclonal antibody biosimilar to rituximab, was approved as a biosimilar to rituximab (Rituxan®) by the US Food and Drug Administration (FDA).  Truxima® was approved for three indications including relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL) as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.

The approval of rituximab-abbs (Truxima®), the first approved biosimilar to rituximab for the treatment of CD20-positive B-cell NHL, was based on a review of a comprehensive data package inclusive of foundational and extensive analytical characterization, nonclinical data, clinical pharmacology, immunogenicity, clinical efficacy, and safety data.

Following extensive product characterization, rituximab-abbs (Truxima®) was shown to be biosimilar to rituximab (Rituxan®), as demonstrated by no clinically meaningful differences in terms of safety, purity, and potency of rituximab-abbs (Truxima®) from the reference product rituximab (Rituxan®). This provided the basis for the FDA approval of rituximab-abb (Truxima®) as a biosimilar to rituximab (Rituxan®), and not as an interchangeable product.

According to the FDA, the biosimilar approval of rituximab-abbs (Truxima®) is the third biosimilar approval in the past month. A biosimilar is a biological product that is approved based on data that shows it is highly similar to a biological product already approved by the FDA, and this could expand patient access to important medicines.

  1. BusinessWire: Celltrion and Teva announce FDA approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for three Non-Hodgkin’s lymphoma indications. 2018 Nov 28. https://www.businesswire.com/news/home/20181128005754/en/Celltrion-Teva-Announce-FDA-Approval-TRUXIMA%C2%AE-rituximab-abbs. [Accessed 2018 Dec 7].
  2. U.S. Food & Drug Administration News Release: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. 2018 Nov 28.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627009.htm.  [Accessed 2018 Dec 7].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox